Trazabilidad en APAC

La Administración de Productos Terapéuticos (TGA) de Australia es la piedra angular de la regulación farmacéutica en el país y opera bajo el Departamento de Salud y Cuidado de Ancianos. Mediante la aplicación rigurosa de la Ley de Productos Terapéuticos de 1989 y los reglamentos relacionados, la TGA garantiza que todos los productos terapéuticos del mercado australiano cumplan con los exigentes estándares de seguridad, calidad y eficacia, salvaguardando así la salud pública y fomentando la confianza de los consumidores.

En el dinámico panorama de la industria farmacéutica china, el cumplimiento de los requisitos de trazabilidad no es solo un mandato reglamentario; es un compromiso con los más altos estándares de seguridad y autenticidad. El plan de trabajo chino para la supervisión electrónica de los productos farmacéuticos y los requisitos de trazabilidad farmacéutica de 2019, regidos por la Administración de Alimentos y Medicamentos (CFDA) de China, se han diseñado meticulosamente para garantizar la integridad de los medicamentos en toda la cadena de suministro.

Indonesia's National Agency of Drug and Food Control (BPOM) has established one of Southeast Asia's most comprehensive pharmaceutical traceability systems through its Track and Trace Anti-Counterfeit (TTAC) framework. This robust regulatory mandate demonstrates Indonesia's commitment to combating counterfeit medicines, enhancing supply chain transparency, and safeguarding public health across its vast archipelago nation.

Japan has pioneered a transformative approach to pharmaceutical tracking and traceability through its mandatory Electronic Package Insert (EPI) system. Since August 2021, the Japanese regulatory framework has fundamentally shifted from traditional paper-based documentation to a comprehensive digital ecosystem that ensures real-time access to critical product information while maintaining robust traceability throughout the pharmaceutical supply chain.

In Kyrgyzstan, the implementation of robust pharmaceutical track and trace regulations represents a significant step forward in ensuring public health protection and supply chain integrity. The country has adopted a comprehensive approach that encompasses pharmaceuticals, consumer goods, and agricultural products, establishing a sophisticated regulatory framework that aligns with international GS1 standards while addressing the unique needs of the Central Asian market.

In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA) is spearheading a transformative approach to pharmaceutical supply chain security through its comprehensive Track & Trace pilot project. This regulatory initiative represents Malaysia's commitment to combating counterfeit medicines, enhancing supply chain transparency, and ultimately safeguarding patient safety across the nation's healthcare ecosystem.